http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 04 Aug 2026 01:39:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html <p>Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL single-dose vials in the United States, a generic equivalent of Merck's Bridion, according to a press release from the company.</p> <p>The company claims the launch occurred on the first day of generic availability for the product in the U.S. market. Sugammadex Injection (100 mg/mL) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.</p> <p>The Bridion brand recorded U.S. sales of approximately $1.6 billion for http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html Tue, 04 Aug 2026 01:39:15 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html <p>Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL single-dose vials in the United States, a generic equivalent of Merck's Bridion, according to a press release from the company.</p> <p>The company claims the launch occurred on the first day of generic availability for the product in the U.S. market. Sugammadex Injection (100 mg/mL) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.</p> <p>The Bridion brand recorded U.S. sales of approximately $1.6 billion for http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html Tue, 04 Aug 2026 01:39:15 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html <p>Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL single-dose vials in the United States, a generic equivalent of Merck's Bridion, according to a press release from the company.</p> <p>The company claims the launch occurred on the first day of generic availability for the product in the U.S. market. Sugammadex Injection (100 mg/mL) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.</p> <p>The Bridion brand recorded U.S. sales of approximately $1.6 billion for http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html Tue, 04 Aug 2026 01:39:15 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html <p>Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL single-dose vials in the United States, a generic equivalent of Merck's Bridion, according to a press release from the company.</p> <p>The company claims the launch occurred on the first day of generic availability for the product in the U.S. market. Sugammadex Injection (100 mg/mL) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.</p> <p>The Bridion brand recorded U.S. sales of approximately $1.6 billion for http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html Tue, 04 Aug 2026 01:39:15 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html <p>Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL single-dose vials in the United States, a generic equivalent of Merck's Bridion, according to a press release from the company.</p> <p>The company claims the launch occurred on the first day of generic availability for the product in the U.S. market. Sugammadex Injection (100 mg/mL) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.</p> <p>The Bridion brand recorded U.S. sales of approximately $1.6 billion for http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html Tue, 04 Aug 2026 01:39:15 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html <p>Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL single-dose vials in the United States, a generic equivalent of Merck's Bridion, according to a press release from the company.</p> <p>The company claims the launch occurred on the first day of generic availability for the product in the U.S. market. Sugammadex Injection (100 mg/mL) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.</p> <p>The Bridion brand recorded U.S. sales of approximately $1.6 billion for http://www.streetinsider.com/FDA/Dr.+Reddy%27s+launches+generic+version+of+Bridion+in+the+US/26859993.html Tue, 04 Aug 2026 01:39:15 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. </p><p> Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Sugammadex+Injection+200+mg2+mL+%28100+mgmL%29+and+500+mg5+mL+%28100+mgmL%29+Single-Dose+Vials%2C+a+Generic+Equivalent+of+Bridion%C2%AE%2C+in+the+United+State/26859992.html Tue, 04 Aug 2026 01:39:00 -0400 500124 A.14869825 DRREDDY O.00555950 O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY